Discontinued — last reported Q2 '13
Vertex Pharmaceuticals Compensation and benefits remained flat by 0.0% to $171.48M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.8%, from $174.63M to $171.48M. Over 2 years (FY 2023 to FY 2025), Compensation and benefits shows an upward trend with a 8.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase often reflects headcount growth or higher performance-based incentives, while a decrease may indicate efficiency initiatives or workforce reductions.
Includes all salaries, wages, bonuses, stock-based compensation, and employee benefit costs for the workforce. This is t...
Highly comparable across all sectors; usually found under 'Personnel' or 'Staffing' expenses.
is_compensation_and_benefits| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $581.20M | $698.50M | $685.90M |
| YoY Change | — | +20.2% | -1.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.